Literature DB >> 15464424

Impact of genetic variation of PPARgamma in humans.

Aline Meirhaeghe1, Philippe Amouyel.   

Abstract

Peroxisome proliferator-activated receptor gamma (PPARgamma) is a transcription factor with a key role in adipocyte differentiation. Since 1997, studies of rare mutations and common polymorphisms of the PPARgamma gene have enabled us to expand our knowledge of the role of this transcription factor in humans. Rare monogenic mutations in PPARgamma have a limited impact on the health of the population due to their low frequency but are associated with severe phenotypes such as severe insulin resistance, partial lipodystrophy, type 2 diabetes and hypertension. Conversely, common polymorphisms of PPARgamma with a relatively high frequency can have a significant impact on the general population. Although they may modulate the risk of developing type 2 diabetes, obesity and cardiovascular diseases, the data remains controversial. This review details and discusses results obtained for PPARgamma variants, whose effects sometimes appear discordant.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15464424     DOI: 10.1016/j.ymgme.2004.08.014

Source DB:  PubMed          Journal:  Mol Genet Metab        ISSN: 1096-7192            Impact factor:   4.797


  48 in total

1.  Role of peroxisome proliferator-activated receptors alpha and gamma in gastric ulcer: An overview of experimental evidences.

Authors:  Lekha Saha
Journal:  World J Gastrointest Pharmacol Ther       Date:  2015-11-06

Review 2.  Dietary fat, genes and insulin sensitivity.

Authors:  José López-Miranda; Pablo Pérez-Martínez; Carmen Marin; Francisco Fuentes; Javier Delgado; Francisco Pérez-Jiménez
Journal:  J Mol Med (Berl)       Date:  2006-12-15       Impact factor: 4.599

3.  Interaction between use of non-steroidal anti-inflammatory drugs and selected genetic polymorphisms in ovarian cancer risk.

Authors:  Simone P Pinheiro; Margaret A Gates; Immaculata De Vivo; Bernard A Rosner; Shelley S Tworoger; Linda Titus-Ernstoff; Susan E Hankinson; Daniel W Cramer
Journal:  Int J Mol Epidemiol Genet       Date:  2010-09-03

Review 4.  Interaction between Pro12Ala polymorphism of PPARγ2 and diet on adiposity phenotypes.

Authors:  Emanuela Lapice; Olga Vaccaro
Journal:  Curr Atheroscler Rep       Date:  2014-12       Impact factor: 5.113

5.  The C-681G polymorphism of the PPAR-γ gene is associated with susceptibility to non-alcoholic fatty liver disease.

Authors:  Chuang-Yu Cao; Yu-Yuan Li; Yong-Jian Zhou; Yu-Qiang Nie; Yu-Jui Yvonne Wan
Journal:  Tohoku J Exp Med       Date:  2012-08       Impact factor: 1.848

Review 6.  Genetic and epigenetic variants influencing the development of nonalcoholic fatty liver disease.

Authors:  Yu-Yuan Li
Journal:  World J Gastroenterol       Date:  2012-12-07       Impact factor: 5.742

7.  Associations between C1431T and Pro12Ala variants of PPARγ gene and their haplotypes with susceptibility to metabolic syndrome in an Iranian population.

Authors:  Hassan Rooki; Monir-sadat Haerian; Pedram Azimzadeh; Reza Mirhafez; Mahmoud Ebrahimi; Gordon Ferns; Majid Ghayour-Mobarhan; Mohammad-Reza Zali
Journal:  Mol Biol Rep       Date:  2014-01-28       Impact factor: 2.316

8.  PPARs in the Renal Regulation of Systemic Blood Pressure.

Authors:  Tamás Roszer; Mercedes Ricote
Journal:  PPAR Res       Date:  2010-06-08       Impact factor: 4.964

9.  Adipose tissue distribution and quantification of PPARbeta/delta and PPARgamma1-3 mRNAs: discordant gene expression in subcutaneous, retroperitoneal and visceral adipose tissue of morbidly obese patients.

Authors:  Josiane Woutheres Bortolotto; Rogério Margis; Angela Cristine Bersch Ferreira; Alexandre Vontobel Padoin; Cláudio Cora Mottin; Regina Maria Guaragna
Journal:  Obes Surg       Date:  2007-07       Impact factor: 4.129

10.  PPARgamma Pro12Ala polymorphism and risk of acute coronary syndrome in a prospective study of Danes.

Authors:  Ulla Vogel; Stine Segel; Claus Dethlefsen; Anne Tjønneland; Anne Thoustrup Saber; Håkan Wallin; Majken K Jensen; Erik B Schmidt; Paal Skytt Andersen; Kim Overvad
Journal:  BMC Med Genet       Date:  2009-06-07       Impact factor: 2.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.